Clin Mol Hepatol.
2023 Feb;29(Suppl):S150-S156. 10.3350/cmh.2022.0362.
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
- Affiliations
-
- 1Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University College of Medicine, Seoul, Korea
- KMID: 2539797
- DOI: http://doi.org/10.3350/cmh.2022.0362
Abstract
- Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of the population worldwide and includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), and cirrhosis. Since NAFLD-associated diseases begin with steatosis, the early diagnosis of steatosis helps to prevent the progression of NASH and fibrosis. In addition, more convenient and easily diagnosable serum biomarkers are becoming crucial in disease diagnosis. In this report, we summarize the known serum biomarkers for liver steatosis and provide guidance for their application in clinical practice.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease
- Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
- Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
- Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
- Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
